Vycor Medical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019
March 27, 2020 at 08:03 am EDT
Share
Vycor Medical, Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was USD 1.481 million compared to USD 1.509 million a year ago. Operating loss was USD 725,129 compared to USD 1.317 million a year ago. Net loss was USD 796,202 compared to USD 1.379 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.08 a year ago.
Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company designs, develops and markets neurological medical devices and therapies. The Company operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment designs, develops and markets medical devices for use in neurosurgery. The NovaVision segment provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Vycor Medical's product Vycor Medical's ViewSite Brain Access System (VBAS) is a next generation retraction and access system. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals. NovaVision's products include Vision Restoration Therapy (VRT), NeuroEyeCoach and Neuro-Eye Therapy (NeEt). The Company operates in the United States and Europe.
VYCOR MEDICAL, INC. 
